Zibotentan

Zibotentan (INN; development code ZD4054) is an experimental anti-cancer drug candidate in development by AstraZeneca.^[1] It is an endothelin receptor antagonist.^[2]

Quick facts Names, Identifiers ...

Zibotentan

Names
Preferred IUPAC name N-(3-Methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide
Other names ZD4054
Identifiers
CAS Number	186497-07-4 Y
3D model (JSmol)	Interactive image
ChEBI	CHEBI:94573
ChemSpider	8085875 N
ECHA InfoCard	100.171.075
IUPHAR/BPS	3539
PubChem CID	9910224
UNII	8054MM4902 Y
CompTox Dashboard (EPA)	DTXSID70870171
InChI InChI=1S/C19H16N6O4S/c1-12-10-21-17(19(23-12)28-2)25-30(26,27)15-4-3-9-20-16(15)13-5-7-14(8-6-13)18-24-22-11-29-18/h3-11H,1-2H3,(H,21,25) N Key: FJHHZXWJVIEFGJ-UHFFFAOYSA-N N InChI=1/C19H16N6O4S/c1-12-10-21-17(19(23-12)28-2)25-30(26,27)15-4-3-9-20-16(15)13-5-7-14(8-6-13)18-24-22-11-29-18/h3-11H,1-2H3,(H,21,25) Key: FJHHZXWJVIEFGJ-UHFFFAOYAL
SMILES O=S(=O)(Nc1ncc(nc1OC)C)c4cccnc4c3ccc(c2nnco2)cc3
Properties
Chemical formula	C19H16N6O4S
Molar mass	424.44 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). N verify (what is YN ?) Infobox references

Close

Zibotentan was granted fast track status for the treatment of prostate cancer by the FDA.

It failed a phase III clinical trial for prostate cancer,^[3] but other trials are planned.^[4] Tolerability of zibotentan plus docetaxel has been evaluated.^[5]

Zibotentan has also been studied in clinical trials for treatment of breast cancer, colorectal cancer, non-small cell lung cancer, ovarian cancer, scleroderma-related renal disease,^[6] bone metastasis, and heart failure.^[7]